Robust Phase 3 Efficacy and Clean Safety Profile Drive Buy Rating on COMPASS Pathways’ CMPS

In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on COMPASS Pathways, with a price target of $29.00.

Ritu Baral has given his Buy rating due to a combination of factors, chiefly the robust Phase 3 efficacy signals and the clean safety profile for COMPASS Pathways’ ‘360 program. The lead study showed a statistically strong and durable reduction in depression scores versus control, with benefits emerging within days and persisting over six weeks, which supports the drug’s potential to differentiate meaningfully in treatment-resistant depression.

Ritu Baral’s rating is based on the view that a sizable subgroup appears highly responsive, with many initial responders converting to remission after a second dose, reinforcing the commercial upside of a repeat-dosing strategy. Favorable tolerability, lack of concerning suicidality signals, and the planned pre-NDA meeting in early Q2 increase confidence in the regulatory path and justify raising the price target, underpinning the Buy recommendation on CMPS.

In another report released today, LifeSci Capital also reiterated a Buy rating on the stock with a $19.00 price target.